Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 13, 2020

Gilead reports reduced mortality risk with remdesivir for Covid-19

Gilead Sciences has reported additional data from the testing of its experimental antiviral drug remdesivir in patients with Covid-19 infection.

Gilead Sciences has reported additional data from the testing of its experimental antiviral drug remdesivir in patients with Covid-19 infection.

The data include findings from a comparative analysis of the Phase III SIMPLE-Severe clinical trial and a real-world retrospective cohort of patients with a severe form of the disease.

According to the analysis, the drug demonstrated an improvement in clinical recovery and a 62% reduction in the risk of mortality compared to standard of care.

Separate analyses were conducted of subgroups from the Phase III SIMPLE-Severe trial, including a review of the safety and efficacy of remdesivir in various racial and ethnic patient subgroups treated in the US.

Data from these analyses revealed that traditionally marginalised racial or ethnic groups who received the drug had similar clinical outcomes as the overall patient population.

In addition, analyses of Gilead’s compassionate use programme showed recovery by day 28 in 83% of paediatric patients and 92% of pregnant and postpartum women with a broad spectrum of disease severity.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The investigators did not report any new safety signals with remdesivir in these populations.

Gilead also started a global, open-label Phase II/III trial to further assess the safety, tolerability and pharmacokinetics of the drug in paediatric patients from birth to less than 18 years of age.

The company is also working to conduct a study for pregnant women.

Gilead Sciences chief medical officer Merdad Parsey said: “We are working to broaden our understanding of the full utility of remdesivir.

“These data presented at the Virtual COVID-19 Conference shed additional light on the use of remdesivir in specific patient populations, including those that may be susceptible to higher rates of Covid-19 infection, as well as others that are particularly vulnerable, including children and pregnant and postpartum women.”

Earlier this month, Gilead launched a Phase Ia trial of an inhaled version of remdesivir to treat Covid-19 patients in the outpatient setting.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU